Coronavirus Protein Structures

Deciphering and comparing the proteins of different coronaviruses forms a basis for understanding SARS-CoV-2 evolution and virus-receptor interactions. This feed follows studies analyzing the structures of coronavirus proteins, thereby revealing potential drug target sites.

January 20, 2022
Open Access

Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants.

MedRxiv : the Preprint Server for Health Sciences
Zhaochun ChenPatrizia Farci
January 20, 2022
Open Access

Extended ensemble simulations of a SARS-CoV-2 nsp1-5'-UTR complex.

PLoS Computational Biology
Shun SakurabaHidetoshi Kono
January 13, 2022
Open Access

Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants

MedRxiv : the Preprint Server for Health Sciences
Z. ChenPatrizia Farci
January 13, 2022

Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses.

Cell Chemical Biology
Valeria NapolitanoKrzysztof Pyrc
December 31, 2021
Open Access

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants.

Frontiers in Immunology
Sisi ShanLinqi Zhang
December 30, 2021

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein.

Emerging Microbes & Infections
Shiqi XuZhong Huang
December 26, 2021
Open Access

Potential coupling between SARS-CoV-2 replicative fitness and interactions of its nucleoprotein with human 14-3-3 proteins

BioRxiv : the Preprint Server for Biology
K. V. TugaevaNikolai N. Sluchanko
December 6, 2021
Open Access

Interactions of SARS-CoV-2 protein E with cell junctions and polarity PDZ-containing proteins

BioRxiv : the Preprint Server for Biology
Y. ZhuCelia Caillet-Saguy
December 1, 2021

Crystal structure of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) frameshifting pseudoknot.

Christopher P Jones, Adrian R Ferré-D'Amaré
November 30, 2021
Open Access

A human monoclonal antibody potently pan-neutralizes SARS-CoV-2 VOCs by targeting RBD invariant sites

BioRxiv : the Preprint Server for Biology
X. WangLilin Ye
November 13, 2021
Open Access

Exposing structural variations in SARS-CoV-2 evolution.

Scientific Reports
Jiaan YangGang Ren
November 10, 2021

Relaxed complex scheme and molecular dynamics simulation suggests small molecule inhibitor of human TMPRSS2 for combating COVID-19.

Journal of Biomolecular Structure & Dynamics
Said A H VuaiDaniel M Shadrack
November 9, 2021

Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.

European Journal of Medicinal Chemistry
Yi-Ting WangDuo-Zhi Chen

Sign up to follow this feed and discover related papers.

Related Feeds

AI-driven COVID-19 Management

Artificial intelligence (AI) offers a powerful new tool that could potentially be instrumental in controling and managing the SARS-CoV-2 virus. The papers in this feed report on the applications of AI to the current pandemic, which may be able to predict the location of the next outbreak, or facilitate new drug design.

Acute viral rhinopharyngitis

Acute viral rhinopharyngitis, also known as "common cold", is an acute, self-limiting viral infection of the upper respiratory tract involving the nose, sinuses, pharynx and larynx. Discover the latest research on acute viral rhinopharyngitis here.


Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

COVID-19 Cardiovascular Complications

Growing evidence shows that COVID-19 can result in serious complications affecting the cardiovascular system, including dysrhythmias, myocarditis, acute myocardial infarction, and heart failure. This feed follows studies investigating the effects of SARS-CoV-2 infection on the heart.

COVID-19 Clinical Diagnosis

COVID-19 patients typically present with high fever and a persistent cough. This feed focuses on clinical diagnosis, including RT-PCR testing for the presence of SARS-CoV-2 and radiographic assessment of lungs.

COVID-19 Clinical Management

While most COVID-19 infections cause only mild to moderate symptoms, severely affected patients, such as those presenting with pneumonia, ARDS or septic shock, require hospitalization. This feed focuses on clinical management of patients using oxygen therapy, ventilation, and other treatment strategies, and covers some medical case reports.

COVID-19 Comorbidities

COVID-19 represents a particular challenge to people with serious chronic medical conditions such as diabetes, hypertension, cardiovascular disease, and chronic lung disease. Research into the intersection between comorbidities and COVID-19 is focusing on risks and treatment outcomes for these patients.

COVID-19 Complications

A growing number of complications associated with COVID-19 has been identified. This feed focuses primarily on cardiovascular and respiratory manifestations in severely ill patients.

© 2022 Meta ULC. All rights reserved